Peripheral Nervous System Agents
12
4
4
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
2 terminated out of 12 trials
66.7%
-19.8% vs benchmark
58%
7 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Natural History of Depression, Bipolar Disorder and Suicide Risk
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
Rescue Quadratus Lumborum Blocks for Post-cesarean Pain
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
Determination of Minimum Effective Volume of Local Anesthetic in Patients Undergoing Ultrasound-Guided Infraclavicular Approach for Brachial Plexus Blockade
Transversus Abdominis Plan Block, Ultrasound or Laparoscopic?